The Centers for Medicare and Medicaid Services (CMS) has granted a unique product reimbursement code (Q-code) for Affymax's Omontys (peginesatide) injection.
Omontys is a once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the US.
The Omontys-specific billing code, Q2047, which will become effective on 1 July 2012 helps to streamline the billing process for dialysis organizations using Omontys.
Affymax chief executive officer John Orwin said the Q-code will help simplify the billing process for reimbursement when used for treating chronic kidney disease (CKD) patients on dialysis.
In March 2012, the US Food and Drug Administration had approved Omontys as a treatment for anemia due to CKD in adult patients on dialysis.
